Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7041MR)

This product GTTS-WQ7041MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7041MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2762MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ2923MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ4253MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ10828MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ3370MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ3028MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ4695MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ540MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 4D5-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW